Page 678«..1020..677678679680..690700..»

UIC Researchers Receive $6M For COVID-19 Treatment To Help Keep People Off Ventilators; Scientist Explains How It Works In Exclusive CBS 2 Interview -…

Posted: August 5, 2021 at 2:46 am

CHICAGO (CBS) Its a treatment that could help keep COVID-19 patients off ventilators, and researchers at the University of Illinois Chicago are on the forefront of developing it.

CBS 2 Investigator Megan Hickey sat down exclusively with the scientist who made the discovery and is getting a $6 million grant to make it happen.

Its called VT-109 and it was created to prevent lung damage that plagues COVID 19 patients. Not only could it help keep patients from having to use a ventilator, it could help save lives.

Yulia Komarova has been working on this drug for years well before COVID-19 hit.

You have to be very persistent when you work in academia, especially on the drug development programs, Komarova said.

FULL INTERVIEW: Yulia Komarova Of UIC On A Treatment That Could Keep COVID Patients Off Ventilators

The UIC associate professor in the Department of Pharmacology and Regenerative Medicine said its been shown to prevent lung damage by tightening the barrier between the bloodstream and the lungs.

Help them to restore the lung function and the function of the other organs because everything depends on the lung function, Komarova said.

Not just prevent lung damage, but this drug has shown to restore lung function. Survival in the animals treated with VT-109, that otherwise would have likely died, was 80%.

Within the first few months of the pandemic, it became clear to Komarova and her team that the implications for human COVID-19 patients were worth investigating.

They applied for the grant in June 2020 and were just awarded $6 million from the Department of Defense.

The studies are very expensive because It involves good laboratory practice, Komarova said.

Theyre still at the beginning of a long road. But the grant is an honor for Komarova, who came to Chicago from Russia two decades ago to do this important work.

Its also an honor for her team at UIC, which is hoping theyll be able to make a significant dent in COVID-19 fatalities in the years to come.

We expect that we can save the majority of the patients, Komarova said.

Komarova hopes to apply for the FDAS new investigational drug program by July 2024, although shes hopeful it could happen before then.

Go here to see the original:
UIC Researchers Receive $6M For COVID-19 Treatment To Help Keep People Off Ventilators; Scientist Explains How It Works In Exclusive CBS 2 Interview -...

Posted in Regenerative Medicine | Comments Off on UIC Researchers Receive $6M For COVID-19 Treatment To Help Keep People Off Ventilators; Scientist Explains How It Works In Exclusive CBS 2 Interview -…

Bioactive Material Sales to Triple Over Current Valuation, Reaching US$ 6.2 Bn by 2031 – Markets Insider

Posted: August 5, 2021 at 2:45 am

Exhibiting a Consolidated Market Attribute, Top Five Players Accounted for more than 20% Revenue Share in Global Bioactive Materials Market

Rising cases of age borne tissue damage especially in geriatric population and increasing use of bioactive materials to create regenerative medicine will drive the bioactive material market. Fact.MR offers incisive survey covering insights into key segments within the market in terms of material, type, and application.

NEW YORK, Aug. 4, 2021 /PRNewswire/ --Fact.MR A Market Research and Competitive Intelligence Provider: The bioactive materials market revenue totaled $2.0 Billion in 2020, according to a Fact.MR study. The overall bioactive materials sales is expected to reach US$ 6.2 billion by the end of 2031, growing at a CAGR of 11.3% for 2020- 31.

The demand for bioactive composite materialswill continue accelerating, rendering the market highly competitive. Amidst this, Fact.MR estimates the top 5 players to account for more than 22% of bioactive materials market in 2021.

Bioactive materials are proven to be effective when used for in-situ drug delivery applications. Researchers have found that bioceramicsare excellent carriers of antibiotic, anti-osteoporotic, and anticancer compounds due to its high carrier suitability.

These materials also have showcased positive results in reducing peri-implant traumas and enabling tissue regrowth. These factors are expected to spur the demand for bioactive materials in bioengineering application.

Besides this, application in regenerate dental hard tissuesand manufacturing dental consumables will emerge as a chief growth driver. The World Health Organization (WHO)reports that around 3.5 billion suffer from oral problem across the world.

Increasing cases of periodontal diseases, problems associated with gingival tissues and dental impairments are fueling the demand for dental consumables which in turn is driving the bioactive materials market demand.

Growing prevalence of musculoskeletal disorders such as osteoporosis, osteoarthritis, and rheumatoid arthritis is fueling the demand for orthopedic implants. Bioactive materials are used in manufacturing orthopedic implants owing to their light weight, high flexibility and biochemical inert properties.

Increasing focus on research activities to identify suitable bioactive materials for implants to reduce trauma amongst patients will pave way for a positive demand outlook.

"Bioactive materials application is expected to soar in the food packaging industry. As a result of commercialization, the demand for packaging material that keeps perishable food items fresh for long period of time is at all-time high. Increasing use of bioactive materials for producing eco-friendly coating for paper packaging will therefore boost the market," said a lead analyst at Fact.MR.

For More Information On How To Improve Your Agricultural Films Market Footprint, Request A Sample Here

https://www.factmr.com/connectus/sample?flag=S&rep_id=6537

Key Takeaways

Prominent Drivers

Key Restraints

Ask Your Agricultural Films Market Related Questions & Get Customized Reports https://www.factmr.com/connectus/sample?flag=RC&rep_id=6537

Competitive Landscape

Rise in geriatric population and increasing demand for tissue repair is motivating market players to develop regenerative medicines through collaboration and partnership with other market players. Growing popularity of tissue engineering has created ideal condition for biomedical suppliers to enter new markets.

For instance, Arthrex signed a distribution agreement with Celularity in July 2021. Under this agreement, Arthrex will gain distribution and commercialization rights to Celularity's orthopedic biomaterial products.

Lineage Cell Therapeutics Inc. under pre-negotiated terms issued a royalty-bearing license to Amasa Therapeutics Inc. in June 2021, to use HyStem technology of Lineage Cell Therapeutics for developing treatment for solid tumors and marketing of treatment therapies.

More Valuable Insights on Bioactive Materials Market

Fact.MR, in its new report, offers an unbiased analysis of the global bioactive materials market, analyzing forecast statistics through 2021 and beyond. The study reveals growth projections on in bioactive materials market on the basis of various segments. These include:

Key Questions Covered in the Report

Explore Fact.MR's Coverage on the Chemical & Materials Domain

Bioceramics Market- Dentists are utilising cutting-edge implant options to avoid tooth loss in individuals suffering from such illnesses. As a result, the popularity of bioceramics is fast increasing. Bioceramic implants are the favoured implant choice among dental practitioners since they are non-toxic and bioinert. Carbon bioceramics sales are expected to increase at a potential CAGR through 2031, owing to its high density and increased fibre strength.

Drug Delivery Systems Market- Polymeric drug delivery is particularly beneficial in the treatment of chronic illnesses such as cancer, particularly solid tumors. It also has a reduced level of toxicity. During the projection period, the polymeric drug delivery segment will account for more than one-third of the worldwide drug delivery systems market. Several advances in the field of medication delivery systems have been made. The inclusion of three-dimensional printing is the most significant of these (3D-printing).

Dental Consumables Market- Dental consumables are used to treat dental illnesses such as tooth restoration, gingival tissue difficulties, dental impairments, dental caries, and periodontal diseases. The growing number of dental disorders around the world is driving the growth of the dental consumables industry. One of the primary drivers of the global dental consumables market is the growing emphasis on physical appearance. Asia Pacific's worldwide dental consumables market share is expected to expand significantly.

About Fact.MR

Market research and consulting agency with a difference! That's why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range from automatic & industry 4.0 to chemical & materialsand retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to uswith your goals, and we'll be an able research partner.

Contact:

Mahendra SinghUS Sales Office:11140 Rockville PikeSuite 400Rockville, MD 20852United StatesTel: +1 (628) 251-1583E: sales@factmr.com

Logo: https://mma.prnewswire.com/media/713666/FactMR_Logo.jpg

View post:
Bioactive Material Sales to Triple Over Current Valuation, Reaching US$ 6.2 Bn by 2031 - Markets Insider

Posted in Regenerative Medicine | Comments Off on Bioactive Material Sales to Triple Over Current Valuation, Reaching US$ 6.2 Bn by 2031 – Markets Insider

Organogenesis (ORGO) falls 2.36% in Light Trading on August 4 – Equities.com

Posted: August 5, 2021 at 2:45 am

Last Price$ Last TradeChange$ Change Percent %Open$ Prev Close$ High$ low$ 52 Week High$ 52 Week Low$ Market CapPE RatioVolumeExchange

ORGO - Market Data & News

Today, Organogenesis Holdings Inc - Class A Incs (NASDAQ: ORGO) stock fell $0.35, accounting for a 2.36% decrease. Organogenesis opened at $14.66 before trading between $15.36 and $14.39 throughout Wednesdays session. The activity saw Organogenesiss market cap fall to $1,854,036,126 on 575,844 shares -below their 30-day average of 721,957.

Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis's comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs.

Visit Organogenesis Holdings Inc - Class A's profile for more information.

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Organogenesis Holdings Inc - Class A and to follow the company's latest updates, you can visit the company's profile page here: Organogenesis Holdings Inc - Class A's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE:The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Continue reading here:
Organogenesis (ORGO) falls 2.36% in Light Trading on August 4 - Equities.com

Posted in Regenerative Medicine | Comments Off on Organogenesis (ORGO) falls 2.36% in Light Trading on August 4 – Equities.com

Pluristem (PSTI) falls 3.67% in Active Trading on August 4 – Equities.com

Posted: August 5, 2021 at 2:45 am

Last Price$ Last TradeChange$ Change Percent %Open$ Prev Close$ High$ low$ 52 Week High$ 52 Week Low$ Market CapPE RatioVolumeExchange

PSTI - Market Data & News

Pluristem Therapeutics Inc (NASDAQ: PSTI), a Building No 5, Haifa, company, fell to close at $3.15 Wednesday after losing $0.12 (3.67%) on volume of 257,328 shares. The stock ranged from a high of $3.28 to a low of $3.15 while Pluristems market cap now stands at $99,981,769.

Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late-stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off- the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a

Visit Pluristem Therapeutics Incs profile for more information.

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Pluristem Therapeutics Inc and to follow the companys latest updates, you can visit the companys profile page here: Pluristem Therapeutics Incs Profile. For more news on the financial markets be sure to visit Equities News. Also, dont forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE:The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Go here to read the rest:
Pluristem (PSTI) falls 3.67% in Active Trading on August 4 - Equities.com

Posted in Regenerative Medicine | Comments Off on Pluristem (PSTI) falls 3.67% in Active Trading on August 4 – Equities.com

A plant that ‘cannot die’ reveals its genetic secrets – The Independent

Posted: August 5, 2021 at 2:39 am

The longest-lived leaves in the plant kingdom can be found only in the harsh, hyperarid desert that crosses the boundary between southern Angola and northern Namibia.

A desert is not, of course, the most hospitable place for living things to grow, let alone leafy greens, but the Namib Desert the worlds oldest, with parts receiving less than 2 inches of precipitation a year is where Welwitschia calls home.

In Afrikaans, the plant is named tweeblaarkanniedood, which means two leaves that cannot die. The naming is apt: Welwitschia grows only two leaves and continuously in a lifetime that can last millenniums.

Most plants develop a leaf, and thats it, says Andrew Leitch, a plant geneticist at Queen Mary University of London. This plant can live thousands of years, and it never stops growing. When it does stop growing, its dead.

Some of the largest plants are believed to be more than 3,000 years old, with two leaves steadily growing since the beginning of the Iron Age, when the Phoenician alphabet was invented and David was crowned King of Israel.

By some accounts, Welwitschia is not much to look at. Its two fibrous leaves, buffeted by dry desert winds and fed on by thirsty animals, become shredded and curled over time, giving Welwitschia a distinctly octopus-like look. One 19th-century director of Kew Gardens remarked, It is out of the question the most wonderful plant ever brought to this country and one of the ugliest.

But since it was first discovered, Welwitschia has captivated biologists including Charles Darwin and botanist Friedrich Welwitsch, after whom the plant is named; it is said that when Welwitsch first came across the plant in 1859, he could do nothing but kneel down on the burning soil and gaze at it, half in fear lest a touch should prove it a figment of the imagination.

When we see that the plant can live in this environment for so long and preserve its DNA and proteins, I feel like we can find hints for how to improve agriculture

In a study published recently in Nature Communications, researchers report some of the genetic secrets behind Welwitschias unique shape, extreme longevity and profound resilience.

Jim Leebens-Mack, a plant biologist at the University of Georgia not involved in the study, says it gives us a foundation for better understanding how Welwitschia does all the crazy stuff that it does.

The Welwitschia genome reflects the plants arid and nutrient-poor surroundings. And its genetic history seems to correspond with environmental history.

Approximately 86 million years ago, after a mistake in cell division, the entire Welwitschia genome doubled during a time of increased aridity and prolonged drought in the region and possibly the formation of the Namib Desert itself, says Tao Wan, a botanist at the Fairy Lake Botanical Garden in Shenzhen, China, and lead author of the study. He says that extreme stress is often associated with such genome duplication events.

Leitch, a co-author of the study, adds that duplicated genes are also released from their original functions, potentially taking on new ones.

However, having more genetic material comes with a cost, Wan says.

The most basic activity for life is DNA replication, he says, so if you have a big genome, it is really energy-consuming to maintain life, especially in such a harsh environment.

To make matters worse, a large amount of Welwitschias genome is junk self-replicating DNA sequences called retrotransposons.

Now that junk needs to be replicated, repaired, Leitch says.

The researchers detected a burst of retrotransposons activity 1 to 2 million years ago, most likely because of increased temperature stress. But to counteract this, the Welwitschia genome underwent widespread epigenetic changes that silenced the junk DNA through a process called DNA methylation.

This process, along with other selective forces, drastically pared down the size and energetic maintenance cost of Welwitschias duplicated library of DNA, Wan says, giving it a very efficient, low-cost genome.

The plants leaves pour out of its base

(Getty/iStock)

The study also found that Welwitschia had other genetic tweaks hidden up its leaves.

The average plant leaf grows from the plants apexes, or the tippy-tops of its stem and branches. But Welwitschias original growing tip dies, and leaves instead pour out of a vulnerable area of the plants anatomy called the basal meristem, which supplies fresh cells to the growing plant, Wan says. A large number of copies or increased activity of some genes involved with efficient metabolism, cell growth and stress resilience in this area may help it continue to grow under extreme environmental stress. In a warming world, the genetic lessons that Welwitschia has to offer may help humans breed hardier, less thirsty crops.

When we see that the plant is able to live in this environment for so long and preserve its DNA and its proteins, I really feel like we can find hints for how to improve agriculture, Leebens-Mack says.

The study also underscores the importance of curiosity-driven research. When you encounter two leaves growing in a desert against all odds, kneel down in the burning soil and take a closer look.

From weird things, you discover weird things that help you understand things that you didnt know you didnt understand, Leitch says.

This article originally appeared in The New York Times

Here is the original post:
A plant that 'cannot die' reveals its genetic secrets - The Independent

Posted in Georgia Stem Cells | Comments Off on A plant that ‘cannot die’ reveals its genetic secrets – The Independent

SucSEED Indovation starts their HealthTech Investment with AyuRythm, a Wellness Platform. – Techstory

Posted: August 5, 2021 at 2:37 am

AyuRythm (HourOnEarth Creative Solutions Pvt Ltd), has secured an undisclosed amount in Fundraise SucSEED Indovation Fund and other several marquee Angel investors as part of its Seed round. AyuRythm is your hyper-personalized digital companion for holistic wellness, with a blend of modern technologies with the ancient science of health assessment and care. Leveraging a simple 30-second pulse analysis (Nadi Pariksha) by placing fingers on smartphone cameras, AyuRythm aims to redefine holistic wellness via personalized recommendations based on an individuals mind, body, and metabolic imbalance.

AyuRythm provides an affordable, instantaneous, complete, personalized, wellness solution on the hands of consumers by integrating cutting edge digital Nadi pariksha (pulse analysis) into mobile phones. Unlike current offerings which focus on expensive devices for physicians, AyuRythm allows consumers to use existing smartphones or wearables. It provides real-time assessment and just-in-time wellness recommendations. AyuRythms assessment and recommendation engines are certified by leading institutions, like SVYASA, HCG, Niraamaya Retreat, Dr Vaidyas, as well as by many individual experts.

Pandemic has reinforced consumers interest in holistic wellness to boost immunity, reduce stress and stay well using ancient methods like Ayurveda and yoga. During the second wave of the pandemic, AyuRythms activation rate increased by 60% and the install base reached ~100,000.

AyuRythm Team

Abhilesh Gupta, the Founder and CEO of AyuRythm said, People are unique and so are their wellness needs. Our aha moment came when we realized more than 90% of consumers are looking for sustainable wellness solutions beyond aggressive exercise like running, weight-lifting and cycling. The overwhelming response from the young adult population during the past few months has certainly validated our hypotheses and opened up exciting possibilities ahead, globally.

He further added that The seed funding we raised from SucSEED Indovation Fund and such established Angel Investors will help us enhance our product and technology capabilities, strengthening our team and accelerate growth.

Speaking on why they have invested in AyuRythm, VVSN Raju Partner of SucSEED Indovation Fund, said, As the pandemic continues, people have become more heedful towards their well-being and there is a need for sustainable personalized wellness. AyuRythm provides digitized real-time assessments by merging Ayurveda with AI algorithm to recommend proactive solutions. They address the underlying causes and treatments of the ailments and stress-related issues which can be accessible and analyzed on smart devices and wearables. As the wellness and healthcare segment is growing fast, AyuRythm provides digitized end-to-end holistic wellness experience.

About the market Potential in this space: Ayurveda (and its allied industry like yoga) industry is on the cusp of high growth and change. It is predicted to be about $15Bn by 2022 and growing at 16% CAGR approximately. The product market is $11Bn and service is around $4Bn. According to the PWC report, about 77% of Indian households have used at least 1 Ayurveda product every year. The Worldwide Ayurveda product market is close to $10Bn growing again at 16%. Yoga products like yoga mats are close to $2Bn in the US alone.

https://www.ayurythm.com

Founded by Ram, Sandeep and Abhilesh, who saw the need for a sustainable and personalized wellness solution for 90% of the population, enabled by everyday devices like smartphones and wearables. Using signal processing and patent-pending algorithms, the startup assesses the users mind, body and metabolic imbalance, and personalizes the diet and activities to help users achieve and maintain their wellness state.

Abhilesh Gupta, Founder and CEO at AyuRythm- A seasoned executive with 25 years of accomplishments in different sectors, geographies, and areas of business. A diehard health and wellness enthusiast.

Ramanath Padmanabhan, Founder & CPO at AyuRythm Seasoned product management executive and a leader with decades of experience in building and scaling health and wellness solutions globally.

Sandeep Acharya, Founder and COO at AyuRythm An Engineer and MBA, having more than a decade of experience in customer data analytics, with expertise in areas of customer intelligence, statistical modelling, and end-to-end analytics landscape setup, in the banking and healthcare sector.

Original post:
SucSEED Indovation starts their HealthTech Investment with AyuRythm, a Wellness Platform. - Techstory

Posted in HCG Diet | Comments Off on SucSEED Indovation starts their HealthTech Investment with AyuRythm, a Wellness Platform. – Techstory

Exicure, Inc. to Present at the BTIG Virtual Biotechnology Conference – Business Wire

Posted: August 5, 2021 at 2:33 am

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today announced that CEO David Giljohann will present at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 2:30pm ET. Exicure will also host 1x1 investor meetings during the conference.

BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest.

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN a lipid-nanoparticle SNAbased therapeutic candidate, for the intrathecal treatment of Friedreichs ataxia (FA). Exicures therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is based in Chicago, IL and in Cambridge, MA.

View original post here:
Exicure, Inc. to Present at the BTIG Virtual Biotechnology Conference - Business Wire

Posted in Biotechnology | Comments Off on Exicure, Inc. to Present at the BTIG Virtual Biotechnology Conference – Business Wire

Anavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021 – Yahoo Finance

Posted: August 5, 2021 at 2:33 am

NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimers disease, Parkinsons disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat in the BTIG Virtual Biotechnology Conference 2021 on Tuesday, August 10, 2021 at 9:30 a.m. EDT.

Webcast for the conference will be available in the Investors section under "Events" of the Anavex corporate website at http://www.anavex.com. To listen to the live event, please contact a BTIG representative with interest.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimers disease, Parkinsons disease, Rett syndrome and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavexs lead drug candidate, ANAVEX2-73 (blarcamesine), successfully completed a Phase 2a clinical trial for Alzheimers disease and recently a Phase 2 proof-of-concept study in Parkinsons disease dementia and a Phase 2 study in adult patients with Rett syndrome. ANAVEX2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimers disease. ANAVEX2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinsons Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX2-73 for the treatment of Parkinsons disease. ANAVEX3-71, which targets sigma-1 and muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimers disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at http://www.anavex.com. You can also connect with the company on Twitter, Facebook, Instagram and LinkedIn.

Story continues

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Companys most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information:

Anavex Life Sciences Corp.Research & Business DevelopmentToll-free: 1-844-689-3939Email: info@anavex.com

Investors:Andrew J. BarwickiInvestor RelationsTel: 516-662-9461Email: andrew@barwicki.com

Continued here:
Anavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021 - Yahoo Finance

Posted in Biotechnology | Comments Off on Anavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021 – Yahoo Finance

Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference – Yahoo Finance

Posted: August 5, 2021 at 2:33 am

PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 9:00 a.m. E.T.

A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.

About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the companys website at http://www.amicusrx.com, and follow us on Twitter and LinkedIn.

CONTACT:

Investors:Andrew FaughnanExecutive Director, Investor Relationsafaughnan@amicusrx.com(609) 662-3809

Media:Diana MooreHead of Global Corporate Communicationsdmoore@amicusrx.com(609) 662-5079

FOLDG

See the original post here:
Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference - Yahoo Finance

Posted in Biotechnology | Comments Off on Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference – Yahoo Finance

Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021 – Yahoo Finance

Posted: August 5, 2021 at 2:33 am

LEXINGTON, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Jennifer Buell, PhD, President and COO of Agenus, will participate in a fireside chat at the BTIG Biotechnology Conference 2021 on Monday, August 9, 2021 from 3:00 p.m. to 3:25 p.m. ET.

BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative.

About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies through its MiNK Therapeutics subsidiary (formerly AgenTus Therapeutics), adjuvants, and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit http://www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

ContactAgenus Investor RelationsJan Medina, CFAAgenus781-674-4490Jan.Medina@agenusbio.com

Agenus Media RelationsKimberly HaKKH Advisors917-291-5744kimberly.ha@kkhadvisors.com

The rest is here:
Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021 - Yahoo Finance

Posted in Biotechnology | Comments Off on Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021 – Yahoo Finance

Page 678«..1020..677678679680..690700..»